|
FDA approves first treatment for rare blood disease
|
21 December 2018 |
|
FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs
|
10 December 2018 |
|
FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
|
30 November 2018 |
|
FDA approves new treatment for patients with acute myeloid leukemia
|
22 November 2018 |
|
FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
|
19 November 2018 |
|
FDA highlights record-breaking number of generic drug approvals in October
|
09 November 2018 |
|
FDA approves new drug to treat influenza
|
26 October 2018 |
|
FDA launches global operation to crack down on websites selling illegal, potentially dangerous drugs
|
23 October 2018 |
|
FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old
|
08 October 2018 |
|
FDA approves first treatment for advanced form of the second most common skin cancer
|
28 September 2018 |
|
FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
|
24 September 2018 |
|
FDA approves new kind of treatment for hairy cell leukemia
|
13 September 2018 |
|
FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
|
10 August 2018 |
|
FDA approves treatment for two rare types of non-Hodgkin lymphoma
|
08 August 2018 |
|
FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
|
20 July 2018 |
|
FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
|
18 July 2018 |
|
FDA warns of imposters sending consumers fake warning letters
|
13 July 2018 |
|
FDA takes steps to encourage more informative labeling on prescription drug and biological products' indications and usage
|
06 July 2018 |
|
FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy
|
25 June 2018 |
|
FDA takes steps to foster greater efficiency in biosimilar development by reconsidering draft guidance on evaluating analytical studies
|
21 June 2018 |